<DOC>
	<DOCNO>NCT02125253</DOCNO>
	<brief_summary>To evaluate therapeutic equivalence l formulation Mometasone Furoate Nasal Spray , 50 mcg market formulation NASONEX® ( mometasone furoate monohydrate ) Nasal Spray , 50 mcg/actuation patient seasonal allergic rhinitis</brief_summary>
	<brief_title>Study Compare Therapeutic Equivalence Mometasone Furoate Nasal Spray , 50 mcg With Nasonex Nasal Spray Relief Signs Symptoms Seasonal Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>If female childbearing potential , negative urine pregnancy test prepare abstain sexual intercourse use reliable method contraception study Documented positive allergic skin test , perform within previous 12 month , one allergens season time study conduct . A minimum two consecutive year previous history seasonal allergic rhinitis pollen/allergen season time study conduct . A score least 6 reflective Total Nasal Symptom Score ( rTNSS ) minimum score least 2 `` nasal congestion '' minimum score least 2 one remain 3 symptom represent 12hours prior screen visit . An average composite score least 6 rTNSS minimum score least 2 `` nasal congestion '' minimum score least 2 one remain 3 symptom represent last 3 day 7day placebo leadin period randomization visit morning first day . randomization visit . Females pregnant , lactate likely become pregnant study . Negative lack document skin allergen test ( perform within previous 12 month ) least one allergens season time study conduct . Patients suffer chronic sign symptom Perennial Allergic Rhinitis , unless investigator assess patient 's current sign symptom clear exacerbation Seasonal Allergic Rhinitis ( SAR ) rather chronic PAR . Patients suffer perennial allergic rhinitis seasonal allergic rhinitis different allergen season time study conduct . Previous history le 2 year seasonal allergic rhinitis pollen/allergen season time study conduct . Any patient meet minimum rTNSS requirement start placebo leadin period long meet requirement prior randomize active treatment period study continue active treatment period . History asthma previous two year require chronic therapy . Occasional acute mild exercise induce asthma allowable condition treatment attack restrict betaagonists . Patients nasal condition , include infectious rhinitis , rhinitis medicamentosa atrophic rhinitis . Clinically significant nasal deformity recent nasal surgery trauma completely heal . Sinus infection within previous 30 day history reoccurring sinus infection . Patient start immunotherapy change dose immunotherapy within 30 day first placebo leadin dose likely start immunotherapy , change current dose study . Treatment oral Candidiasis within 30 day start study current oral Candidiasis infection . Upper respiratory tract infection within previous 30 day . Patients history tuberculosis . Patients presence glaucoma , cataract , ocular herpes simplex , conjunctivitis eye infection relate diagnosis SAR within 14 day enrollment . The patient recent exposure ( 30 day ) risk expose chicken pox measles . Patients untreated fungal , bacterial , systemic viral infection within previous 30 day . Use ophthalmic steroid within 14 day nasal , inhaled systemic steroid within 30 day study start . Use reference product , Nasonex® within 3 month study start . Use intranasal systemic secondgeneration antihistamine within10 day enrollment . Use intranasal cromolyn within 14 day enrollment . Use intranasal systemic firstgeneration antihistamine , leukotriene receptor antagonist nasal decongestant within 3 day enrollment . Use tricyclic antidepressant within 30 day enrollment Patients attentiondeficit disorder treat methylphenidate containing product stable dose regimen least 30 previous day remain dosing regimen throughout study . Desensitization therapy seasonal allergen cause patient allergic rhinitis within previous 6 month . Previous SAR and/or PAR proven unresponsive steroid therapy . Any known hypersensitivity mometasone , steroids component study nasal spray . Significant history current evidence chronic infectious disease , system disorder , organ disorder medical condition Investigator 's opinion would place study patient undue risk participate could jeopardize integrity study evaluation . Receipt drug part research study within 30 day prior first placebo leadin dose . Planned travel outside local area 2 consecutive day 3 day total , patient 's participation study . Previous participation study . The patient currently smoke cigarette , cigar , and/or pipe heavy smoker The patient share household another patient currently enrol study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>